SCHEMBL845251

SCHEMBL845251

CCC(=O)N1CCC[C@H]1C(=O)Nc1ccc(/C=C/c2ccc(NC(=O)[C@@H]3CCCN3C(=O)CC)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.50
ALDH1A1 P00352 3/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NPC1 O15118 1/20 0.48
LMNA P02545 2/20 0.47
GAA P10253 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 2/20 0.47
MAPK1 P28482 2/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
TSHR P16473 1/20 0.45
EP300 Q09472 1/20 0.44
CREBBP Q92793 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845228 0.88 HCRTR1 (0.49) PABPC1ALDH1A1CYP2C9CYP2C19NPC1
SCHEMBL844899 0.88 NPC1 (0.52) PABPC1ALDH1A1CYP2C9CYP2C19NPC1
SCHEMBL844884 0.87 HTT (0.48) PABPC1ALDH1A1CYP2C9CYP2C19NPC1
SCHEMBL845235 0.87 MAPK1 (0.52) PABPC1ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL13272192 0.87 MAPK1 (0.52) PABPC1ALDH1A1CYP2C9CYP2C19LMNA
SCHEMBL845206 0.87 CYP2C9 (0.52) PABPC1ALDH1A1CYP2C9CYP2C19NPC1
SCHEMBL844902 0.87 ALDH1A1 (0.47) PABPC1ALDH1A1CYP2C9CYP2C19NPC1
SCHEMBL845245 0.87 PTPN1 (0.50) PABPC1ALDH1A1CYP2C9CYP2C19NPC1
SCHEMBL845519 0.86 ALDH1A1 (0.46) PABPC1ALDH1A1CYP2C9CYP2C19NPC1
SCHEMBL845295 0.85 KDM4E (0.61) PABPC1ALDH1A1CYP2C9CYP2C19NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed